About Gubra
Gubra is a company based in Hørsholm (Denmark) founded in 2008. The company has 260 employees as of December 31, 2024. Gubra has completed 1 acquisition, including MiniGut. Gubra operates in a competitive market with competitors including Tigermed, BioQual, Gentronix, Shanghai Semero Biotechnology and Aquila BioMedical, among others.
- Headquarter Hørsholm, Denmark
- Employees 260 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gubra A/S
-
Annual Revenue
$37.02 M (USD)29.63as on Dec 31, 2024
-
Net Profit
-$5.08 M (USD)18.03as on Dec 31, 2024
-
EBITDA
-$4.11 M (USD)10.93as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
260
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Gubra
Gubra is a publicly listed company on the OMXCOP with ticker symbol GUBRA in Denmark, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Gubra
Unlock access to complete
Senior Team
10 people
Research Team
7 people
Software Development Team
7 people
Principal Team
5 people
Leadership Team
4 people
Sales and Marketing
3 people
Human Resources and Administration
3 people
Finance and Accounting
2 people
Unlock access to complete
Funding Insights of Gubra
Detailed funding history for Gubra
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gubra
Gubra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include MiniGut.
Investment portfolio details for Gubra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Pre-clinical models and regulatory compliance services are offered by MiniGut.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Gubra
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Gubra
Detailed financials for Gubra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gubra Comparisons
Peer comparison for Gubra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gubra
Gubra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tigermed, BioQual, Gentronix, Shanghai Semero Biotechnology and Aquila BioMedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug development and preclinical services are provided by Tigermed.
|
|
| Locked | Locked | Locked |
Contract research on infectious disease models is conducted.
|
|
| Locked | Locked | Locked |
In-vitro and in-vivo genetic toxicology screening services are provided.
|
|
| Locked | Locked | Locked |
Diversified preclinical services for brain-related disorders are provided.
|
|
| Locked | Locked | Locked |
Preclinical services in immunology, regeneration, neuroscience, and histology are provided.
|
Detailed competitors of Gubra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gubra
Complete news archive for Gubra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gubra
Gubra was founded in 2008.
Gubra is headquartered in Hørsholm, Denmark.
As of Dec 31, 2024, the latest employee count at Gubra is 260.
Annual revenue of Gubra is $37.02M as on Dec 31, 2024.
Gubra is a preclinical CRO offering its services for developing drugs and treatments for NAFLDNASH, Diabetes and Obesity. The companys service portfolio includes In Vivo Pharmacology, Histology And Stereology, Molecular Biology, and Assays. The company has in vivo models such as diet-induced obese mouse models, accelerated diet-induced obese mouse models, obob or obese models, dbdb models, Male ZDF (Zucker Diabetic Fatty) rats, for studying efficacy, Mechanism of Action and Metabolic Phenotyping studies and for establishing Proof of Concept. Their Histology and Stereology services include Histochemical Staining, Immunohistochemistry (singledoubletriple labeling), Pancreas biology, gut morphometry, liver pathology Unbiased quantitative analyses and CNS Stereology.
Yes, Gubra is publicly traded on OMXCOP under the ticker symbol GUBRA.
Gubra has made 1 acquisition, including MiniGut.
The ticker symbol of Gubra is GUBRA on OMXCOP.